Guidelines for the use of epoetin in cancer patients: a much-needed step forward in standardizing anemia treatment
- 1 October 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 102 (7) , 2697-2698
- https://doi.org/10.1182/blood-2003-02-0427
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfaEuropean Journal Of Cancer, 2003
- Epoetin Alfa Treatment Results in Clinically Significant Improvements in Quality of Life in Anemic Cancer Patients When Referenced to the General PopulationJournal of Clinical Oncology, 2003
- Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapyBritish Journal of Cancer, 2002
- Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of HematologyBlood, 2002
- Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled TrialJournal of Clinical Oncology, 2001